In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted.
Titolo: | Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). |
Autori di Ateneo: | |
Autori: | Angelucci E1; SANTINI, VALERIA; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S. |
Anno di registrazione: | 2014 |
Rivista: | |
Volume: | 92 |
Pagina iniziale: | 527 |
Pagina finale: | 536 |
Abstract: | In the absence of randomized, controlled trial data to support iron chelation therapy in transfusion-dependent patients with myelodysplastic syndromes (MDS), continued evidence from large prospective clinical trials evaluating the efficacy and safety of iron chelation therapy in this patient population is warranted. |
Handle: | http://hdl.handle.net/2158/911536 |
Codice ONU Sustainable Development Goals (SDG): | Goal 3: Good health and well-being for people |
Appare nelle tipologie: | 1a - Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
angelucci2014.pdf | Articolo | PDF editoriale | Open Access | Accesso pubblicoVisualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.